{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:27:20Z","timestamp":1781087240885,"version":"3.54.1"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Diabetic macular edema (DME) is one of the leading causes of vision impairment in diabetic patients. The aim of this study was to evaluate the cost-effectiveness of faricimab (Vabysmo\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ), the first bispecific antibody targeting VEGF-A and ANG-2, for treating DME in China.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We conducted a cost-effectiveness analysis from the perspective of the Chinese health system using a Markov model to simulate long-term outcomes in DME patients. The model population was based on the Chinese subgroup from the RHINE trial, with a mean starting age of 58.7\u00a0years. Faricimab, administered according to a personalized treatment interval regimen following four initial monthly injections, was compared with aflibercept (every 8\u00a0weeks) and with ranibizumab and conbercept (both following a pro-re nata dosing regimen). The model incorporated clinical efficacy, adverse events, quality-adjusted life years and direct costs. Extensive sensitivity analyses (one-way and probabilistic) were performed to assess the robustness of the findings.\n                    <jats:bold>Results:<\/jats:bold>\n                    Over 20\u00a0years, faricimab gained 0.42, 0.61, 0.80 incremental quality-adjusted life years compared with aflibercept, conbercept, ranibizumab, while reducing treatment costs by 33,315 Chinese Yuan (CNY), 59,061 CNY and 12,314 CNY, respectively. Sensitivity analyses confirmed the robustness of these results, consistently demonstrating faricimab as a dominant and cost-effective treatment option for DME.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This first Chinese cost-effectiveness study of faricimab for DME shows it enhances visual outcomes and reduces costs, supporting its adoption and providing evidence for healthcare decision-making on reimbursement and resource allocation.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0190","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:13:11Z","timestamp":1773828791000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2876-7920","authenticated-orcid":false,"given":"Fenghao","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"},{"name":"International Research Centre for Medicinal Administration, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"},{"name":"International Research Centre for Medicinal Administration, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-8135","authenticated-orcid":false,"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2443-9299","authenticated-orcid":false,"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceutical Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xia","sequence":"additional","affiliation":[{"name":"Shanghai Roche Pharmaceutical Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9006-8787","authenticated-orcid":false,"given":"Christian","family":"Buehrer","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-3574","authenticated-orcid":false,"given":"Sheng","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"},{"name":"International Research Centre for Medicinal Administration, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","article-title":"Diabetic macular edema: pathogenesis and treatment","volume":"54","author":"Bhagat N","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol. 54(1), 1\u201332 (2009).","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1753-0407.12644","article-title":"International Diabetes Federation 2017","volume":"10","author":"Carracher AM","year":"2018","unstructured":"Carracher AM, Marathe PH, Close KL. International Diabetes Federation 2017. J. Diabetes 10(5), 353\u2013356 (2018).","journal-title":"J. Diabetes"},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1038\/s41467-023-39864-w","article-title":"Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China","volume":"14","author":"Hou X","year":"2023","unstructured":"Hou X, Wang L, Zhu D Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China. Nat. Commun. 14(1), 4296 (2023).","journal-title":"Nat. Commun."},{"issue":"4","key":"e_1_3_8_6_2","first-page":"363","article-title":"A 5-year prospective study of Type 2 diabetes patients in Shanghai Xinjing Community1.The incidence and risk factors of diabetic retinopathy and diabetic macular edema in Chinese Type 2 diabetes residents","volume":"34","author":"Jin P","year":"2016","unstructured":"Jin P, Peng J, Zou H. A 5-year prospective study of Type 2 diabetes patients in Shanghai Xinjing Community1.The incidence and risk factors of diabetic retinopathy and diabetic macular edema in Chinese Type 2 diabetes residents. Chinese J. Exp. Ophthalmol. 34(4), 363\u2013367 (2016).","journal-title":"Chinese J. Exp. Ophthalmol."},{"issue":"11","key":"e_1_3_8_7_2","first-page":"851","article-title":"Clinical practice guidelines for diabetic retinopathy in China (2014)","volume":"50","author":"Chinese Ophthalmological Society","year":"2014","unstructured":"Chinese Ophthalmological Society. Clinical practice guidelines for diabetic retinopathy in China (2014). Chinese J. Ophthalmol. 50(11), 851\u2013865 (2014).","journal-title":"Chinese J. Ophthalmol."},{"issue":"7","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0161-6420(87)33527-4","article-title":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema","volume":"94","year":"1987","unstructured":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 94(7), 761\u2013774 (1987).","journal-title":"Ophthalmology"},{"issue":"6","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0002-9394(14)74789-0","article-title":"Subretinal fibrosis after laser photocoagulation for diabetic macular edema","volume":"113","author":"Smith CW","year":"1992","unstructured":"Smith CW, Guyer DR, D'Amico DJ. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am. J. Ophthalmol. 113(6), 652\u2013656 (1992).","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema","volume":"131","author":"Wong TY","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K Faricimab treat-and-extend for diabetic macular edema. Ophthalmology 131(6), 708\u2013723 (2024).","journal-title":"Ophthalmology"},{"issue":"10326","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, Phase III trials","volume":"399","author":"Wykoff CC","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, Phase III trials. Lancet 399(10326), 741\u2013755 (2022).","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_8_12_2","article-title":"Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): 1-year results from China subpopulation of Phase III RHINE trial","volume":"64","author":"Sun X","year":"2023","unstructured":"Sun X, Li X, Han M. Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): 1-year results from China subpopulation of Phase III RHINE trial. Invest. Ophthalmol. Vis. Sci. 64(8), Poster 2700 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/OPTH.S235267","article-title":"Intravitreal aflibercept versus laser photocoagulation in Asian patients with diabetic macular edema: the VIVID-East study","volume":"14","author":"Chen Y-X","year":"2020","unstructured":"Chen Y-X, Li X-X, Yoon YH Intravitreal aflibercept versus laser photocoagulation in Asian patients with diabetic macular edema: the VIVID-East study. OPTH 14, 741\u2013750 (2020).","journal-title":"OPTH"},{"issue":"3","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"on behalf of the REFINE study group","year":"2019","unstructured":"on behalf of the REFINE study group, Li X, Dai H Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefes Arch. Clin. Exp. Ophthalmol. 257(3), 529\u2013541 (2019).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"10","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","volume":"106","author":"Liu K","year":"2022","unstructured":"Liu K, Wang H, He W Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br. J. Ophthalmol. 106(10), 1436\u20131443 (2022).","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s41669-023-00465-4","article-title":"Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): a UK analysis","volume":"8","author":"B\u00fchrer C","year":"2024","unstructured":"B\u00fchrer C, Paling T, Gale R, Paulo T, Bagijn M. Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): a UK analysis. PharmacoEconomics Open 8(3), 445\u2013457 (2024).","journal-title":"PharmacoEconomics Open"},{"issue":"9","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman AR","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology 127(9), 1201\u20131210 (2020).","journal-title":"Ophthalmology"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0174"},{"issue":"8","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/aos.13824","article-title":"A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration","volume":"96","author":"Elshout M","year":"2018","unstructured":"Elshout M, Webers CAB, Van Der Reis MI, Schouten JSAG. A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration. Acta Ophthalmologica 96(8), 770\u2013778 (2018).","journal-title":"Acta Ophthalmologica"},{"key":"e_1_3_8_20_2","volume-title":"Health economics: National Institute for Health and Care Excellence 2018","year":"2018","unstructured":"Health economics: National Institute for Health and Care Excellence 2018, NICE (2018)."},{"key":"e_1_3_8_21_2","volume-title":"China Population and Employment Statistics Yearbook \u2013 2022","year":"2022","unstructured":"China Population and Employment Statistics Yearbook \u2013 2022. China Statistics Press (2022)."},{"issue":"8","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1167\/iovs.08-1676","article-title":"Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling","volume":"49","author":"Christ SL","year":"2008","unstructured":"Christ SL, Lee DJ, Lam BL, Zheng DD, Arheart KL. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Invest. Ophthalmol. Vis. Sci. 49(8), 3318 (2008).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"e_1_3_8_23_2","first-page":"402","article-title":"Pharmacoeconomic evaluation of anti- VEGF drugs and laser photocoagulation for the treatment of DME in China","volume":"55","author":"Liu J","year":"2020","unstructured":"Liu J, Jiang Y, Ni W, He X. Pharmacoeconomic evaluation of anti- VEGF drugs and laser photocoagulation for the treatment of DME in China. Chin. Pharmaceut. J. 55(5), 402\u2013407 (2020).","journal-title":"Chin. Pharmaceut. J."},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.arr.2010.07.002","article-title":"Falls in aged people of the Chinese mainland: epidemiology, risk factors and clinical strategies","volume":"9","author":"Wang J","year":"2010","unstructured":"Wang J, Chen Z, Song Y. Falls in aged people of the Chinese mainland: epidemiology, risk factors and clinical strategies. Ageing Res. Rev. 9, S13\u2013S17 (2010).","journal-title":"Ageing Res. Rev."},{"issue":"15","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.21037\/atm-20-1334","article-title":"Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration","volume":"8","author":"Chen R","year":"2020","unstructured":"Chen R, Wu B. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. Ann. Transl. Med. 8(15), 939\u2013939 (2020).","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/gps.1103","article-title":"A community-based study of depression in older people in Hefei, China\u2014the GMS-AGECAT prevalence, case validation and socio-economic correlates","volume":"19","author":"Chen R","year":"2004","unstructured":"Chen R, Hu Z, Qin X, Xu X, Copeland JRM. A community-based study of depression in older people in Hefei, China\u2014the GMS-AGECAT prevalence, case validation and socio-economic correlates. Int. J. Geriat. Psychiatry 19(5), 407\u2013413 (2004).","journal-title":"Int. J. Geriat. Psychiatry"},{"issue":"7","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"A565","DOI":"10.1016\/j.jval.2016.09.1267","article-title":"Burden of low vision and blindness in Chinese elder popullation: data from field survey","volume":"19","author":"Guan X","year":"2016","unstructured":"Guan X, Lin F, Wang L, Ni Q, Shi L. Burden of low vision and blindness in Chinese elder popullation: data from field survey. Value Health 19(7), A565\u2013A566 (2016).","journal-title":"Value Health"},{"issue":"5","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","article-title":"Valuing condition-specific health states using simulation contact lenses","volume":"12","author":"Czoski-Murray C","year":"2009","unstructured":"Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health 12(5), 793\u2013799 (2009).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40273-019-00800-w","article-title":"Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review","volume":"37","author":"Maniadakis N","year":"2019","unstructured":"Maniadakis N, Konstantakopoulou E. Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review. Pharmacoeconomics 37(8), 995\u20131010 (2019).","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1007\/s12325-017-0620-x","article-title":"Challenges associated with estimating utility in wet age-related macular degeneration: a novel regression analysis to capture the bilateral nature of the disease","volume":"34","author":"Hodgson R","year":"2017","unstructured":"Hodgson R, Reason T, Trueman D Challenges associated with estimating utility in wet age-related macular degeneration: a novel regression analysis to capture the bilateral nature of the disease. Adv. Ther. 34(10), 2360\u20132370 (2017).","journal-title":"Adv. Ther."},{"issue":"1","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archopht.118.1.47","article-title":"Utility values and age-related macular degeneration","volume":"118","author":"Brown GC","year":"2000","unstructured":"Brown GC. Utility values and age-related macular degeneration. Arch. Ophthalmol. 118(1), 47 (2000).","journal-title":"Arch. Ophthalmol."},{"key":"e_1_3_8_32_2","volume-title":"China Guidelines for Pharmacoeconomic Evaluations: A Manual (2022). (1st Edition)","author":"Liu G","year":"2020","unstructured":"Liu G. China Guidelines for Pharmacoeconomic Evaluations: A Manual (2022). (1st Edition). China Market Press (2020)."},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/fampra\/cmh417","article-title":"The impact of diabetic retinopathy: perspectives from patient focus groups","volume":"21","author":"Coyne KS","year":"2004","unstructured":"Coyne KS. The impact of diabetic retinopathy: perspectives from patient focus groups. Fam. Pract. 21(4), 447\u2013453 (2004).","journal-title":"Fam. Pract."},{"issue":"5","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma A","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye 34(5), 802\u2013804 (2020).","journal-title":"Eye"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:28:58Z","timestamp":1774888138000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.57264\/cer-2025-0190"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0190","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e250190"}}